PMC4899657_01
Enhanced abdominal CT findings. a At baseline. Huge hypoenhanced tumors showed mainly in peripheral areas of the liver (segments 2 and 3). b About 3 years later. The liver tumors have gradually decreased in size. c About 5 years later. The liver tumors have shrunk considerably.
cro-0009-0134-g01.jpg
PMC4899657_01_cro-0009-0134-g01.jpg
F1
Contrast-enhanced CT imaging revealed multiple hypoenhanced tumors (max. size 60 mm diameter) mainly in peripheral areas of the liver (fig. 1a, fig. 2a). CT findings revealed that the tumors were shrinking slightly; 33 months later, the tumors obviously showed a partial response in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) (fig. 1b, fig. 2b). Also 60 months later, they were shrinking significantly (fig. 1c, fig. 2c). Currently, the patient is still taking sorafenib, and the partial response is still continuing.
a, b Microscopic examination of biopsy specimens. The liver parenchyma was replaced by a fibrotic tissue containing moderate dysplastic polygonal tumor cells within spindle- or round-shaped nuclei. An immunohistochemical analysis revealed the cells to be positive for CD31.
cro-0009-0134-g03.jpg
PMC4899657_01_cro-0009-0134-g03.jpg
F3
Needle biopsy specimens from the tumors revealed that the liver parenchyma was replaced by a fibrotic tissue containing moderate dysplastic polygonal tumor cells within spindle- or round-shaped nuclei (fig. 3a). Immunohistochemical examinations revealed that the tumor cells showed positive staining for CD31 (fig. 3b).